We have independently established internal production capabilities that comply with GMP. Currently, the GMP production facility covers an area of approximately 2000 square meters and has a CMC team of nearly 40 people, covering the entire CAR-T development cycle. It can be used for the production of lentiviral vectors and clinical production of cell therapy products. Integrated production is beneficial for improving efficiency, strengthening control, and reducing costs. At present, there are 4 independent production lines in the factory, with an estimated annual production capacity of 500 batches of autologous CAR-T products. The quality system complies with ISO and cGMP standards.